Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Alimentary Pharmacology & Therapeutics|April 13, 2011
Clinical predictors of poor outcomes among patients with nonvariceal upper gastrointestinal bleeding in EuropeA Lanas, L Aabakken, J Fonseca, et al.
Transplantation|August 15, 2001
The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosisG V Papatheodoridis, S Davies, A P Dhillon, et al.
Journal of Hepatology|December 1, 1995
Hepatitis E virus infection in a cohort of patients with acute non-A, non-B hepatitisM A Psichogiou, N C Tassopoulos, G V Papatheodoridis, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2009
Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort studyE K Manesis, G V Papatheodoridis, G Touloumi, et al.
Gut|August 14, 1999
Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimensG V Papatheodoridis, S G Barton, D Andrew, et al.
Journal of Viral Hepatitis|August 20, 2005
Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatmentsV Sypsa, G Touloumi, G V Papatheodoridis, et al.
Journal of Viral Hepatitis|April 23, 2014
The usefulness of transient elastography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infectionG V Papatheodoridis, S Manolakopoulos, A Margariti, et al.
Alimentary Pharmacology & Therapeutics|July 17, 2009
Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre studyE Tsochatzis, S Manolakopoulos, G V Papatheodoridis, et al.
Gut|November 21, 2007
Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infectionG V Papatheodoridis, E Hadziyannis, E Tsochatzis, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2018
A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis BH L Y Chan, D Messinger, G V Papatheodoridis, et al.
Pageof 7